X
Dear User,
On May 25, 2018, Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 (General Data Protection Regulation) came into force. We encourage you to familiarise yourself with information about the processing of personal data on the PolskieRadio.pl website.
1.The Data Administrator is Polish Radio S.A., based at 77/85 Niepodległości Ave., 00-977, Warsaw.
2.On issues regarding your data, please contact the Data Protection Officer, e-mail: iod@polskieradio.pl, tel. 22 645 34 03.
3.Personal data may be processed for marketing purposes based on consent.
4.Personal data may be shared solely for the purpose of proper implementation of services defined in the privacy policy.
5.Personal data will not be transferred outside the European Economic Area or to an international organisation.
6.Personal data will be stored for 5 years after an account is deactivated, in accordance with the law.
7.You have the right to access your personal data, correct it, to have it moved or deleted, or to limit its processing.
8.You have the right to object to further processing, and in the case of voicing consent to the processing of personal data, you have the right to withdraw your consent. The exercise of the right to withdraw consent does not affect any processing that has already taken place.
9.You have the right to lodge a complaint with the supervisory authority.
10.Polish Radio S.A. declares that no automated decisions are made when personal data is processed, and that profiling is not used.
For more information on this subject, please read our personal data and privacy policy.
I UNDERSTAND
English Section

EU Commission head says AstraZeneca contract contains binding orders: Reuters

29.01.2021 09:30
BERLIN, Jan 29 (Reuters) - The European Union's contract with AstraZeneca for its COVID-19 vaccine contains binding orders, EU Commission head Ursula von der Leyen said on Friday, as the bloc continues to press the drugmaker to deliver supplies as promised.
The Amsterdam-based European Medicines Agency is on Friday expected to authorize the AstraZenecaOxford COVID-19 vaccine for use across the EU.
The Amsterdam-based European Medicines Agency is on Friday expected to authorize the AstraZeneca/Oxford COVID-19 vaccine for use across the EU.Photo: Robin Utrecht/ABACAPRESS.COM

The EU has been locked in a row with AstraZeneca, which partnered with Britain's Oxford University to develop its vaccine, after the drugmaker said last week it would cut deliveries in the first quarter due to production issues at a Belgian factory.

An EU official said that meant the EU would receive 31 million doses in the period, or 60% less than initially agreed, piling pressure on the 27-country bloc which has lagged vaccination campaigns in Israel, Britain and the United States.

"There are binding orders and the contract is crystal clear," von der Leyen told Deutschlandfunk radio, adding it contained clear delivery amounts for December and the first three quarters of 2021.

"AstraZeneca has also explicitly assured us in this contract that no other obligations would prevent the contract from being fulfilled," she added.

Von der Leyen's comments contradict statements by AstraZeneca Chief Executive Pascal Soriot, who told newspapers on Tuesday the EU contract was based on a "best-effort" clause and did not commit the company to a specific timetable for deliveries.

Soriot has also said the EU was late to strike a supply contract so the company did not have enough time to iron out production problems at a vaccine factory run by a partner in Belgium.

Von der Leyen said the "best-effort" cause was only valid as long as it was not clear whether AstraZeneca could develop a vaccine. She also said there was no "order sequencing" stipulation and that it mentioned four production sites, two of which are in Britain.

The EU wants to make a redacted version of the contract public later on Friday, she said.

The EU contract with AstraZeneca is an advance purchase agreement for the supply of at least 300 million doses provided the vaccine is approved as safe and effective, with doses delivered in stages. It is expected to be approved by the European Medicines Agency (EMA) on Friday.

(Reporting by Caroline Copley; Editing by Maria Sheahan and
Mark Potter)

Source: Reuters